Tests that look at the number of circulating tumor cells in the bloodstream may help predict cancer patients' response to treatment, according to two separate studies presented at the American Society of Clinical Oncology's meeting. In one study, U.S. scientists analyzed a clinical trial of 1,195 prostate cancer patients who received Johnson & Johnson's cancer drug Zytiga and found that those who had the lowest levels of tumor cells in their blood had a higher chance of survival.

Full Story:

Related Summaries